For security purposes
FOR SECURITY PURPOSES - because Internet Explorer is no longer supported by Microsoft, we suggest that you interact with our secure site through one of our supported browsers - Google Chrome, Firefox, or MS Edge. If you continue to use this website with Internet Explorer you do so at your own risk and you may encounter problems.
Applications
Lopinavir & Ritonavir Tablets USP (COVID-19) Luna 5 µm C8(2) 150 x 4.6 mm
25914
Separation Mode: Reversed Phase
Reversed Phase
USP
C8(2)
HPLC
Anti-HIV Agents
Pharmaceutical/Biopharmaceutical
Therapeutic / Clinical
Therapeutic / Clinical

Lopinavir & Ritonavir Tablets USP (COVID-19) Luna 5 µm C8(2) 150 x 4.6 mm

Analytes
1Ritonavir
2Lopinavir
Details
Official Method: USP
LC Conditions (App ID: 25914)
Column:
Brand Name:
Luna
Part No:
Phase Name:
C8(2)
System:
Agilent Technologies 1260 Infinity Hybrid SFC/UHPLC Agilent Technologies 1260 Infinity Hybrid SFC/UHPLC
Sample Note:
Buffer = 4.1 g Potassium Phosphate monobasic in 1 L of Water Solution A = 50:50 ACN:Buffer Samples were dissolved and diluted in Solution A
Similar Applications
search
No Data